DaVita flags lower revenue per treatment, reaffirms annual forecast

Impact · against what's priced in

DaVita faces headwinds as the end of pandemic-era subsidies drives patients out of Obamacare plans, leading to lower dialysis enrollments and revenue per treatment. While the company reaffirmed its annual forecast, the structural decline in per-unit revenue creates a negative pressure on margins.

DVA−0.50: No priced-in read yet
In context: The company reported lower revenue per treatment due to declining enrollments as patients left Obamacare plans following the expiration of pandemic-era subsidies.
Read from the article alone

DaVita flags lower revenue per treatment, reaffirms annual forecast

Search tags

DaVita flags lower revenue per treatment, reaffirms annual forecast

What matters in this story

DaVita flags lower revenue per treatment, reaffirms annual forecast

What matters in this story

How each ticker is affected

Track these names every morning.